Synovium-derived mesenchymal stem cells: a new cell source for musculoskeletal regeneration

Tissue Eng Part B Rev. 2009 Mar;15(1):75-86. doi: 10.1089/ten.teb.2008.0586.

Abstract

Ever since synovium-derived mesenchymal stem cells (SMSCs) were first identified and successfully isolated in 2001, as a brand new member in MSC families, they have been increasingly regarded as a promising therapeutic cell species for musculoskeletal regeneration, particularly for reconstructions of cartilage, bones, tendons, and muscles. Besides the general multipotency in common among the MSC community, SMSCs excel other sourced MSCs in higher ability of proliferation and superiority in chondrogenesis. This review summarizes the latest advances in SMSC-related studies covering their specific isolation methodologies, biological insights, and practical applications in musculoskeletal therapeutics of which an emphasis is cast on engineered chondrogenesis.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Bone and Bones / metabolism
  • Cartilage / cytology
  • Cell Proliferation
  • Cells, Cultured
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Mesenchymal Stem Cells / cytology
  • Mesenchymal Stem Cells / immunology
  • Mesenchymal Stem Cells / metabolism
  • Mesenchymal Stem Cells / physiology*
  • Muscle, Skeletal / cytology
  • Osteoarthritis / therapy
  • Phenotype
  • Synovial Membrane / cytology*
  • Tendons / metabolism
  • Tissue Engineering / methods*

Substances

  • Immunosuppressive Agents